This paper, produced by the International Myeloma Working Group (IMWG), provides an updated definition of high-risk myeloma based on cytogenetics and provides recommendations for the optimum treatment for this group of myeloma patients.
This paper, written by the International Myeloma Working Group (IMWG), reviews the current evidence, and provides recommendations for the management of patients with relapsed myeloma.
This paper by the International Myeloma Working Group, reviews the available evidence and provides recommendations for the management of myeloma-related kidney disease
These guidelines, produced by an expert panel on behalf of the European Myeloma Network (EMN), provide recommendations for the management of the most common complications of myeloma, including bone and kidney disease.
This NICE guidance outlines recommendations for children and adults with suspected cancer, including primary care investigations and referral recommendations to secondary care.
These updated guidelines, produced by the British Society of Haematology and Myeloma UK summarise a national consensus for the use of imaging in the diagnosis and management of myeloma patients.
This paper, written by the International Myeloma Working Group (IMWG), reviews the current evidence, and provides recommendations for the optimal use of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and related diseases, including smouldering myeloma and solitary plasmacytoma.
These guidelines, produced by the British Society of Haematology (BSH) and the UK Myeloma Forum (UKMF), highlight the late and long-term effects of myeloma and its treatments, and summarise the national consensus for the screening and management of these effects.
Pain is one of the most common and debilitating symptoms of progressive myeloma. This guidance written by NICE outlines safe use of opioids for adults with advanced disease.
This NICE guidance covers medical and NHS service recommendations for children and adults who have received a diagnosis of a haematological cancer.